Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SPRY
ARS PHARMACEUTICALS, INC.
NASDAQ
$5.89
▼ DOWN 2.32% (-0.14)

KEY STATISTICS

Market Cap$584.90 M
52w High$13.15
52w Low$4.91
Dividend Yield—
Frequency—
P/E-2.70
Volume1.19M
Shares Out.99.30M

COMPANY

LEADERSHIP

Donn Casale
CHIEF EXECUTIVE
Donn Casale

COMPENSATION 2026

Salary$700,000
Stock Awards$0
Incentive Plan Pay$315,000
All Other Comp.$2,465,290
Total$9,656,400

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 4, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
163

PRICE TARGET

Target High$26.00
Target Low$25.00
Target Median$25.50
Target Consensus$25.50

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$44.84M
NOV
9
MON

PRICE

$5.89 ▼ DOWN 2.32% (−$0.14)
$5.85$5.92$6.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.89

About ARS Pharmaceuticals, Inc.

https://ars-pharma.com ↗

ARS Pharmaceuticals, Inc. develops Neffy, a low-dose intranasal epinephrine spray with absorption technology for patients at risk of severe allergic reactions, and is based in San Diego since 2015.

INDUSTRY

Biotechnology

A PRODUCT ARS PHARMACEUTICALS, INC. IS KNOWN FOR

neffy® (epinephrine nasal spray)
neffy® (epinephrine nasal spray)

Neffy® is the first FDA-approved, needle-free nasal spray for emergency treatment of severe allergic reactions, offering an easy alternative to auto-injectors, with recent pediatric approvals and international launches highlighting its innovation ...

COMPETITORS

COMPETITOR
AMPH COMPARE
AMRX COMPARE
AQST COMPARE
VTRS COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q4-2025Q1-2026Q2-2026
Product$12.8M $59.39M ▲$17.45M ▼$26.21M ▲

Revenue by Geography

MapREGIONQ1-2026Q2-2026
UNITED STATES$17.45M $26.21M ▲
DENMARK$2.78M $5.77M ▲
NonUS$2.45M $4.08M ▲
JAPAN— $3.37M

ETFS HOLDING THIS STOCK

ETFS HOLDING
99
LISTED HERE
15
RANKED BY POSITION SIZE
XBI
0.12% · 2.4M
VTS.AX
0.00% · 1.7M
XSU.TO
0.01% · 1.6M
SCHA
0.01% · 308.2K
LABU
0.08% · 88.6K
XRSG.L
0.01% · 56.4K
ONEQ
0.00% · 40.4K
DFAS
0.00% · 39.6K
RSSL
0.01% · 29.2K
IBBQ
0.04% · 6.2K
BIB
0.02% · 3.5K
TILT
0.00% · 2.7K
VETS
0.05% · 1.8K
USFMDN.MX
0.00% · 217
RESM
0.01% · 126

INSTITUTIONAL OWNERSHIP

SHARES OWNED
70.95%
HOLDERS
284
TOP 12 OF 284 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
10.9M sh · $87M
Rubric Capital Management LP
8.5M sh · $68.41M
Orbimed Advisors LLC
8.3M sh · $66.39M
Deerfield Management Company, L.P. (Series C)
7.5M sh · $75.41M
Millennium Management LLC
6.0M sh · $48.04M
Blackrock, Inc.
5.3M sh · $42.54M
Tyro Capital Management LLC
4.5M sh · $35.72M
Abrdn Plc
4.2M sh · $33.41M
Blackrock Inc.
4.1M sh · $34.76M
Sr One Capital Management, LP
4.0M sh · $40.33M
State Street Corp
3.7M sh · $29.88M
Vanguard Group Inc
3.5M sh · $40.88M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
Smith Margaret Ekins
— · —
2026-08-17
★
OFFICER: PRESIDENT
Casale Donn
Purchase · 898.5K shares
2026-07-01
★
DIRECTOR
Shah Pratik
Purchase · 30.0K shares
2026-06-24
★
DIRECTOR
Kelly Michael
Purchase · 30.0K shares
2026-06-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
OVERWEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
Leerink Partners OUTPERFORM Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
PVLA$149.97COMPARE
NBTX$41.23COMPARE
GHRS$27.94COMPARE
TYRA$24.94COMPARE
KURA$12.66COMPARE
SVRA$5.26COMPARE
ABUS$5.07COMPARE
RZLT$4.62COMPARE